CAPR 55% premarket after FDA panel votes against Co's duchenne heart disease therapy
CAPR 55% premarket after FDA panel votes against Co's duchenne heart disease therapy
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.